Financings in Brief: Genzyme Tissue Repair
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Tissue Repair: Plans for a secondary offering of common stock valued at $40 mil. are outlined in a recent registration statement filed with the Securities and Exchange Commission. The Cambridge, Massachusetts maker of tissue repair products would use the proceeds for general corporate purposes. Credit Suisse First Boston, Cowen & Company, and PaineWebber are managing the offering...